SCD is only one blood disorder that can benefit from Aruvant’s modified fetal hemoglobin–based gene therapy. The company is already working on applying ARU-1801 to the treatment of β-thalassemia.

inherited RBC disorders, or as a response to drugs or other toxins Howell-Jolly Bodies Nuclear remnants seen in RBCs after Wright's staining Seen in types of anemia, asplenia/hyposplenia ...